Active Surveillance for Localized Prostate Cancer

A New Paradigm for Clinical Management
Softcover Nachdruck of the original 2. Auflage 2018
ISBN: 978-3-319-87375-6
Verlag: Springer International Publishing

Buch, Englisch, 250 Seiten, Previously published in hardcover, Format (B × H): 178 mm x 254 mm, Gewicht: 563 g

Reihe: Current Clinical Urology

This fully updated and revised new edition provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in prostate cancer.  The book reviews new data about molecular characteristics of the disease, profiles the new grading system for prostate cancer introduced in 2015, and provides new perspectives about imaging of prostate cancer, as well as the role of targeted biopsies. The text summarizes the role of biomarkers and MRI in patient selection and management and details the world wide results of active surveillance. Specific chapters address communication and ethical issues, QOL outcomes, economic aspects, and psycho-social aspects of surveillance. The role of focal therapy for low risk disease is summarized, and the data supporting preventive interventions during surveillance reviewed. This text will serve as a very useful resource for physicians and researchers dealing with, and interested in this common malignancy, as it provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts.    

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Klotz, Laurence

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Allgemeinmedizin, Familienmedizin
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Urologie, Andrologie, Venerologie

Inhaltsverzeichnis

Table of Contents

Chapter 1        Cancer Overdiagnosis and Overtreatment

                        Laurence Klotz

Chapter 2        Can We Screen and Still Reduce Overdiagnosis?

                        Peter Ka-Fung Chiu and Monique J. Roobol

Chapter 3        The Role of Fear in Overdiagnosis and Overtreatment

                        Iona Heath

Chapter 4        Ethical and Legal Considerations in Active Surveillance for Prostate Cancer

                        Lionne D.F. Venderbos

Chapter 5        Gleason 6 Tumors Should Still Be Labeled As Cancer

                        Angelo M. De Marzo and Jonathan I. Epstein

Chapter 6        Risk Based Selection for Active Surveillance

                        Jan F.M. Verbeek, Monique J. Roobol and Ewout W. Steyerberg

Chapter 7        Surveillance at the Margins: Management of High Volume Gleason 6, PSA > 10,                           or Gleason 3+4

                        Laurence Klotz

Chapter 8        How Should Patients on Active Surveillance be Followed?

                        Frank-Jan H. Drost, Monique J. Roobol, and Leonard P. Bokhorst

Chapter 9        Triggers for Intervention

                        Tuomas Mirtti, Hanna Vasarainen, and Antti Rannikko

Chapter 10      MR Imaging in Prostate Tumor Volume Assessment: How Accurate?

                        Ivo G. Schoots and Theo H. van der Kwast

Chapter 11      Can MRI Replace Biopsy in Men on Surveillance?

                        Francesco Giganti, Vasilis Stavrinides, and Caroline M. Moore

Chapter 12      Tissue Based Markers for Risk Prediction

                        Chad A. Reichard and Eric A. Klein

Chapter 13      International AS Registry:  The Movember Foundation’s Global Action Plan                                  Prostate Cancer Active Surveillance Initiative

                        Sophie M. Bruinsma, Daan Nieboer, Tim Hulsen, Liying Zhang, Rachelle Kirk-                              Burnnand, Sam Gledhill, and Mark Buzza on behalf of the Movember                                            Foundation’s GAP3 Steering Committee

Chapter 14      Better Informed Decision Making to Optimize Patient Selection

                        Lara Bellardita, Paola Dordoni, Letizia De Luca, Julia Paola Menichetti Delor,                               Riccardo Valdagni

Chapter 15      How Does QOL Compare Between Surveillance and Active Treatment?

                        Lionne D.F. Venderbos, Stephanie Danielle Brandhof, and Ida J. Korfage

Chapter 16      The Potential Benefits of Diet and Physical Activity among Active Surveillance                            Patients with Low-Burden Prostate Cancer

                        Stacey A. Kenfield, David Tat, and June M. Chan

Chapter 17      Is there a Role for Pharmacologic Manipulation to Prevent Progression in Men on              Active Surveillance?  The Role of 5-ARIs, Statins, and Metformin

                        Roy Mano and David Margel

Chapter 18      The Update of Active Surveillance around the World: Utilization and Outcomes

                        Jeffrey J. Tosoian, Ridwan Alam, Abbey Lepor, Stacy Loeb

Chapter 19      Tissue Preservation – Active Surveillance and Focal Therapy as Complimentary Strategies

                        Juan Gomez Rivas and Mark Emberton

Chapter 20      The Economics of Active Surveillance for Prostate Cancer

                        Robert B. Lurvey and Marc A. Dall’Era

Chapter 21      Research Questions in Active Surveillance

                        Laurence Klotz

Über Autor(innen)

Laurence Klotz, MD, FRCSC, CM

Professor of Surgery, University of Toronto

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada